Skip to content
The Nexus
DossierENTITY

Revolution Medicine

Coverage of Revolution Medicine in the Nexus archive.

Earliest in view: Jul 25 · 11:30 UTCMost recent: Jul 25 · 11:30 UTC
Co-mentioned in this coverage
daraxonrasibtopic1Innovation Treadmilltopic1Lipitortopic1Pfizerorganization1Human Genome Projecttopic1FDAorganization1cell and gene therapiestopic1
Recent coverage
  • HEALTHJul 25 · 11:30 UTCFORTUNE
    When 10,000 doctors stood up and cheered for a cancer drug — America’s innovation machine made it possible

    A cancer drug, daraxonrasib, developed by Revolution Medicine, nearly doubled survival rates for pancreatic cancer, sparking a standing ovation at a conference. The article highlights the U.S. innovation model, the 'Innovation Treadmill,' which balances high drug prices with rapid generic substitution to sustain medical breakthroughs. It contrasts U.S. drug access with European delays and discusses trends like genetic advancements and AI in biotech.

Revolution Medicine · Dossier · The Nexus